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.2012.07.0Abstract The present investigation was designed with the intention to formulate a versatile 5-ﬂu-
orouracil(5-FU) matrix tablet surpassing issues associated with current conventional chemothera-
peutic drug delivery systems. The novel 5-FU matrix tablet fulﬁlls therapeutic needs by
engineering matrix tablets utilizing chitosan–sodium alginate interpolyelectrolyte complex (IPEC).
IPEC was characterized by Fourier transform infrared spectroscopy (FTIR), differential scanning
calorimetry (DSC) and X-ray diffraction (XRD). The matrix tablets were formulated utilizing IPEC
alone and in combination with chitosan, sodium alginate and sodium deoxycholate as permeation
enhancer. Pharmaceutical properties, swelling studies, in vitro dissolution and diffusion studies,
mucoadhesive studies and in vivo studies were performed for formulated 5-FU. The selected chito-
san–sodium alginate IPEC offers pH independent 5-FU release in comparison to alone or physical
mixture of chitosan and sodium alginate. Furthermore, novel matrix tablets demonstrated signiﬁ-
cantly higher bioadhesive properties with controlled 5-FU release without the initial burst effect
and also demonstrated a higher permeation of 5-FU. To conclude, the developed novel 5-FU
matrix tablets pave way as an excellent alternative for cancer treatment which could potentially
minimize the dose dependent side effects and provide better patient compliance.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
5-Fluorouracil(5-FU) has been widely used as an effective che-
motherapeutic agent and drug of choice in oropharyngeal ca-
ner, colorectal cancer, stomach cancer and cervical cancer




. Production and hosting by Elsev
02acid with pka values of 8.0 and 13.0 and is highly polar in nat-
ure (Rudy and Senkowski, 1973; Williams and Barry, 1991).
After oral administration, 5-FU is poorly absorbed with erra-
tic variation in bioavailability ranging between 0% and 80%.
5-FU after parenteral administration is rapidly eliminated with
apparent terminal half life of approximately 8–20 min (Dol-
lery, 1999; Singh et al., 2005). On intravenous administration
5-FU produces severe systemic toxic effects including gastroin-
testinal, hematological, neural, cardiac and dermatological ori-
gin (Diasio and Harris, 1989). In such cases, local
administration of 5-FU would be very advantageous instead
of oral or parenteral drug delivery.
Most publications on 5-ﬂurouracil focused on only single
drug delivery like buccal gels (Dhiman et al., 2008), buccal tab-ier B.V. All rights reserved.
Table 1 Formulation chart.
Ingredients F1 F2 F3 F4 F5 F6
5-Flurouracil 20 20 20 20 20 20
IPEC 40 80 80 80 80 80
Chitosan –– –– 10 20 20 20
Sodium alginate –– –– 10 20 20 20
Sodium deoxycholate –– –– –– –– 3 4.5
Microcrystalline cellulose 85 45 25 5 2 0.5
Talc 5 5 5 5 5 5
Weight in mg.
Total weight of tablet is 150 mg.
178 M.S. Pendekal, P.K. Tegginamatlets (Libero et al., 2010),and cervical patches (Woolfson et al.,
1995). Based on these, 5-FU will be suitable for transbuccal/
vaginal/rectal drug delivery. Hardly any articles reported on
permeation studies and histological effects of 5-FU. Literature
review revealed that there is no single drug delivery system
available that can be given either through buccal, vaginal or
rectal route. The prime goal has to design 5-ﬂurourcil multi-
purpose tablets with greater efﬁcacy, potency, adoptability to
need, minimal toxic effects and better patient compliance than
the established marketed product.
Polymeric drug delivery systems are mainly designed for the
efﬁcient delivery of active drug. Among various polymeric
drug delivery systems, interpolyelectrolyte complexes are the
most newer and efﬁcient form. Interpolyelectrolyte complexes
(IPEC) have been used as a new class of polymeric carriers for
novel drug delivery systems (Peppas and Khare, 1993; Berger
et al., 2004; Nam et al., 2004; Moustanﬁne et al., 2005).
Chitosan, is a natural cationic polysaccharide obtained by
partial deacetylation of chitin, consisting of glucosamine
(GA) and N-acetyl-glucosamine (NAc-GA) linked by b-1,4
glucosidic bonds (Madihally and Matthew, 1999; Dang and
Leong, 2006). Alginate is another natural anionic linear poly-
saccharide composed of a-L-guluronic and b-D-mannuronic
acid residues (Gombotz and Wee, 1998; Augst et al., 2006).
The carboxylate moieties on alginate can ionically interact
with the protonated amines on chitosan, forming physical
cross-linked hydro-gels known as polyelectrolyte complex
(PEC) Takahashi et al., 1990; Baruch and Machluf, 2006.
Numerous 5-FU formulations have developed with various
formulation strategies such as buccal gels, cervical patches, lip-
osomes, and nanoparticles. However, these formulations are
organ speciﬁc and require stringent procedures for ﬁnal formu-
lation. Cost of product development is too high as the proce-
dures are more speciﬁc for liposomes and nanoparticles.
The versatile 5-FU matrix tablets offer a highly convenient
preparation, patient compliance, minimizes toxic effects, cost
effective and moreover suitable for industrial production.
2. Materials and methods
2.1. Materials
5-FU was obtained from Strides Arcolab Ltd., Bangalore, In-
dia. Chitosan (Marine chemical, Cochin, India, Deacetylation
degree: 85%, viscosity: <200 mPa s, moisture content: <10%,
ash content: <1%, insoluble: <1%, pH: 3–6, particle size: 80–
100 mesh). Sodium alginate (sigma Aldrich, nature: pH: 7.2,
viscosity: 20–400 mPa s, loss on drying: 615.0%, sulphated
ash: 30.0–36.0%). Sodium deoxycholate, microcrystalline cel-
lulose and Talc were from Zydus Cadila, India. All other
chemicals and reagents used were of analytical grade.
2.2. Preparation of chitosan–sodium alginate
interpolyelectrolyte complex (IPEC)
The chitosan–alginate interpolyelectrolyte complex was pre-
pared from chitosan solution at 4.0% w/v in 1% w/w acetic
acid solution and sodium alginate solution at 4.0% w/v in
water. Each solution was heated separately at 70–80 C. Both
solutions were mixed with agitation until the mixture reached
room temperature. Then it was left to rest for 2 h. The inter-polyelectrolyte complex (IPEC) was thoroughly washed with
distilled water and was then separated from water by centrifu-
gation for 30 min at 10000 rpm. Thereafter IPEC was dried in
a hot air oven and the dried complex was ground with a grin-
der. The powder was passed through a 200 lm sieve and used
for further study.
2.3. Fourier transform infrared (FT-IR) spectroscopy study
The infrared absorption spectra of Chitosan, sodium alginate
and IPEC were analyzed using a FT-IR spectrophotometer
(8400S, Shimadzu, Japan). The pellets were prepared by press-
ing the sample with potassium bromide.
2.4. Differential scanning calorimetry (DSC)
Thermal analysis was carried out using a differential scanning
calorimeter (DSC 50, Shimadzu Scientiﬁc Instruments, Japan)
for Chitosan, sodium alginate and IPEC. The samples were
placed in an aluminum-sealed pan and preheated to 200 C.
The sample was cooled to room temperature and then reheated
from 40 to 400 C at a scanning rate of 10 C/min.
2.5. Powder X-ray Diffraction
Powder X-ray diffraction patterns on chitosan, sodium algi-
nate and IPEC were obtained by using an X-ray Diffractome-
ter (Miniﬂex II Desktop X-ray Diffractometer, Rigaku
Corporation, Tokyo, Japan). The samples were scanned from
6 to 40 (2h) with an increment of 0.02 and measurement
time of 10 s/increment.
2.6. Preparation of mucoadhesive matrix tablet
Mucoadhesive tablets were fabricated by direct compression
method as shown in Table 1. The accurate quantity of 5-FU
and excipients was weighed. They were passed through sieve
and thoroughly mixed using mortar and pestle. The blend
was lubricated and then compressed into compacts by direct
compression method using 8-mm ﬂat-faced punches in KBr
press (Technosearch, Mumbai, India) at 1 ton pressure with
a dwell time of 1 s.
2.7. Swelling studies
The swelling index of the prepared mucoadhesive 5-FU tablets
was determined by weighing ﬁve tablets and recording their
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The total weight was recorded (W1). Four milliliters of phos-
phate buffer pH 6.8 (similarly with simulated vaginal ﬂuid of
pH 4.2 and pH 7.4) was added to each beaker and then placed
in an incubator at 37 ± 0.5 C. At time intervals of 2, 4, 6 and
8 h excess water was carefully removed, and the swollen tablets
were weighed (W2). The experiment was repeated three times,
and the average of W1 and W2 was reported.
The swelling index was determined from the formula.
SI ¼ ðW2W1Þ=W1 100 ð1Þ2.8. In vitro release of matrix tablets
The drug release rate from buccal compacts was studied using
the orbital shaking incubator using (Remi CIS 24, India)
30 mL of phosphate buffer pH 6.8. The temperature was main-
tained at 37 ± 0.5 C and 50 rpm (rotation per min). For every
one hour of time interval 3 mL sample was withdrawn, ﬁltered
through a Millipore ﬁlter of 0.45 lm pore size and assayed
spectrophotometrically at 266 nm. Immediately after each
sample withdrawal, a similar volume of phosphate buffer pH
6.8 was added to the dissolution medium.
The drug release rates from vaginal tablets were studied in
500 ml of simulated vaginal ﬂuid pH 4.2 in type II dissolution
apparatus. The temperature was maintained at 37 ± 0.5 C
and 50 rpm. For every one hour of time interval 10 mL sample
was withdrawn, ﬁltered through a Millipore ﬁlter of 0.45 lm
pore size and assayed spectrophotometrically at 265 nm. Imme-
diately after each sample withdrawal, a similar volume of sim-
ulated vaginal ﬂuid was added to the dissolution medium.
In vitro drug release for rectal tablets was performed using
the dissolution apparatus I; 500 mL phosphate buffer (pH
7.4) maintained at 37 ± 0.5 C was used as a dissolution med-
ium. Basket was rotated at 50 rpm. 10 mL aliquots were taken
at periodic time intervals and replaced by equal volume of phos-
phate buffer. The solution was suitably diluted and the absor-
bance was taken at 267 nmusingUV visible spectrophotometer.
2.9. Bioadhesive strength
Bioadhesive strength of the compacts was measured using
modiﬁed physical balance as recently discussed (Deshmukh
et al., 2009). In vitro bioadhesion studies were carried out using
sheep buccal mucosa and modiﬁed two-armed balance. The
phosphate buffer pH 6.8 was used as the moistening ﬂuid. A
glass stopper was suspended by a ﬁxed length of thread on
one side of the balance and was counter balanced with the
weights on the other side. Fresh sheep buccal mucosa was col-
lected from the slaughter house. It was scrapped off from the
connective tissues and a thin layer of buccal mucosa was sep-
arated which was stored in Tris buffer until used for the bioad-
hesion study. A circular piece of sheep buccal mucosa was cut
and ﬁxed to the tissue holder and was immersed in phosphate
buffer pH 6.8 and the temperature was maintained at
37± 1 C. Then the tablet was ﬁxed to a glass stopper with
the help of cyanoacrylate adhesive and it was placed on the
buccal mucosa by using a preload of 50 gm and kept aside
for 3 min to facilitate adhesion bonding. After preloading
time, the preload was removed and the weights were added
on the other side of the balance until tablet detaches fromthe sheep buccal mucosa. The weight required to detach tablet
from buccal mucosa was noted.
2.10. Ex vivo permeation study
Permeation study was carried out for the optimized formula-
tion using Franz diffusion cell. The tablet was placed in the do-
nor compartment on the sheep mucosa. The mucosal layer is on
donor compartment. The receptor compartment was ﬁlled with
phosphate buffer pH 6.8. The temperature was maintained at
37 ± 0.5 C and 50 rpm. The amount of 5-FU permeated
through sheep mucosa was determined by withdrawing 3 ml
of aliquots from the receptor compartment using a syringe
and immediately replacing the same volume of solution.
2.11. In vivo X-ray studies
The in vivo X-ray studies were approved by the Institutional
Animal Ethics Committee of JSS College of Pharmacy (My-
sore, Karnataka, India). The study was performed on a
healthy female rabbit, weighing between 1 and 1.5 kg. F3 for-
mulation was modiﬁed by adding 20 mg of X-ray grade bar-
ium sulfate (20 mg 5-FU was replaced). The prepared tablet
was placed in the buccal mucosa of healthy rabbit. During
the study, the rabbit was not allowed to eat or drink. The rab-
bit was exposed to X-ray examinations and photographs were
taken at 1st and 8th hr after administration of the tablet. Sim-
ilar procedure was followed for vaginal and rectal delivery.
2.12. Kinetic analysis
Drug release from simple swellable systems may be described
by the power law expression and is deﬁned by the following
equation.
Mt=M1 ¼ K1tn ð2Þ
where Mt is the amount of drug released at time t, M1 is the
overall amount of drug released, K1 is the release constant; n is
the release or diffusional exponent and Mt/M1 is the cumula-
tive drug concentration released at time t (or fractional drug
release).
The release exponent (n) value was used for interpretation
of the release mechanism from the compacts. The dissolution
data were modeled by using PCP disso v2.01 (Bharathi Vidhy-
apeeth, Deemed University, Pune, Maharashtra, India).
2.13. Statistical analysis
Statistical analyses of all data were undertaken using Graph-
Pad prism version 5.0 (Graphpad software Inc, San Diego,
California, USA).
3. Results and discussions
In our previous paper, studies on chitosan polymers on Eudra-
git RL and RS 100 on buccal patches of tizanidine were eval-
uated (Mohamed and Pramod, 2012a). Later, it was also
shown in our laboratory that the interpolymer complex be-
tween Chitosan and Carbopol 71G as a suitable polymer
for the development of novel drug delivery of miconazole for
candidiasis (Mohamed and Pramod, 2012b).
Figure 2 Superimposed DSC thermograms of chitosan, sodium
alginate and IPEC.
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Chitosan, we identiﬁed that chitosan is well suitable for partic-
ular pH and alone is not suitable for novel drug delivery. In
contrast, chitosan–sodium alginate interpolyelectrolyte com-
plex showed high potential as a matrix former and used as a
new class of polymeric carriers for tissue engineering in the
form of scaffolds (Li et al., 2005), membranes (Chen et al.,
2006), ﬁbers (Iwasaki et al., 2004) and microcapsules (George
and Abraham, 2006). Therefore based on the extensive review
and previous experience on above cited polymers, chitosan–so-
dium alginate interpolyelectrolyte complex is taken into pres-
ent investigation.
3.1. Characterization of IPEC
The interaction between chitosan and sodium alginate has
been studied by several investigators (Xiaoxia et al., 2009; Bru-
no et al., 2006). The studies indicated that IPEC could be
formed by the electrostatic interaction between the COO–
group of sodium alginate and NH3
+ group of chitosan in solu-
tions. Fig. 1 shows the superimposed IR spectra of Chitosan,
sodium alginate and IPEC in 1000–2000 cm1 and 1400–
1800 cm1.
The degree of deacetylation of Chitosan is 85%, the amine
group of 2-aminoglucose unit and the carbonyl group of 2-
aminoglucose unit of chitosan showed absorption bands at
1589 and 1656 cm1, respectively (Tien et al., 2003). Sodium
alginate FTIR spectra showed strong absorption bands at
1610 cm1 and 1417 cm1 due to carboxyl anion stretching
vibrations(asymmetric and symmetric) and at 1124 cm1Figure 1 FT-IR Spectra of Chitosan, sodium alginate and IPC in 2000–1000 and 1800–1400 cm1.
Figure 3 Superimposed XRD spectra of Chitosan, sodium
alginate and IPEC.
Figure 4a Swelling studies of formulations in pH 4.2. ¤ F1, h
F2, 4 F3, · F4, F5, d F6 (mean ± SD, n= 3).
Figure 4b Swelling studies of formulations in pH 6.8. ¤ F1, h
F2, 4 F3, · F4, F5, d F6 (mean ± SD, n= 3).
Figure 4c Swelling studies of formulations in pH 7.4. ¤ F1, h
F2, 4 F3, · F4, F5, d F6 (mean ± SD, n= 3).
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spectra, spectra of the physical mixture of two polymers or
immiscible polymers will be the sum of the spectra of the indi-
vidual compounds, whereas for polymers after electrostatic
interaction, there will be changes in the IR spectra such as
Wavenumber shifts, band broadening and new absorption
bands that are evidence of the polymers miscibility (Stuart,
2004). The interpolymer complex showed similar spectra to
that of sodium alginate: a broad band at 1610 cm1 with
two other bands at 1415 cm1 and 1454 cm1 indicating most
of the alginate in the IPEC was deprotonated. The reduction in
the intensity of band at 1415 cm1 also conﬁrmed the proton-
ation. The band at 1543 cm1 could be assigned to the NH3
+
group of chitosan and the broadness of the band at 1610 cm1
to 1643 cm1 arose from the overlapping bands from the
amide of chitosan and carboxyl group of alginate.
Fig. 2 shows the DSC thermograms of chitosan, sodium
alginate and chitosan–sodium alginate IPEC. The DSC ther-
mograms of pure chitosan, exhibit one broad endothermic
peak at 110 C associated to the evaporation of bound water,
a glass transition at 240 C and an exothermic peak at about
320 C attributable to the polymer degradation. This includes
saccharide ring dehydration, depolymerization and decompo-
sition of deacetylated and acetylated chitosan units (Mathew
et al., 2006; Sarmento et al., 2006). These peaks are in agree-Table 2 Pharmaceutical properties.
Formulation code Thickness (mm) Hardness (N) Friability (%) Weight (mg) Drug content (%)
F1 2.01 ± 0.001 73 ± 4 0.08 149.7 ± 0.523 99.96 ± 0.07
F2 2.02 ± 0.001 75 ± 4 0.04 149.6 ± 1.00 99.91 ± 0.03
F3 2.01 ± 0.002 79 ± 4 0.03 149.5 ± 0.753 99.91 ± 0.08
F4 2.03 ± 0.003 74 ± 3 0.05 150.0 ± 0.532 99.92 ± 0.09
F5 2.02 ± 0.002 75 ± 3 0.05 150.1 ± 0.512 99.89 ± 0.12
Figure 5 Mucoadhesive strength of formulations.
Figure 6a Dissolution proﬁle of formulations F1–F4 in pH 4.2.
¤ F1, h F2, 4 F3, · F4 (mean ± SD, n= 3).
Figure 6b Dissolution proﬁle of formulations F1–F4 in pH 6.8.
¤ F1, h F2, 4 F3, · F4 (mean ± SD, n= 3).
Figure 6c Dissolution proﬁle of formulations F1–F4 in pH 7.4.
¤ F1, h F2, 4 F3, · F4 (mean ± SD, n = 3).
182 M.S. Pendekal, P.K. Tegginamatment with other reported studies (Neto et al., 2005; Sankalia
et al., 2007). Sodium alginate thermogram exhibits one endo-
thermic and exothermic peak at 100 C and 250 C. The ﬁrst
endothermic peak is a broad peak assigned to the evaporation
of water from hydrophilic groups in the polymers and the
second exothermic peak resulted from degradation of polyelec-
trolytes due to dehydration and depolymerization reactions
most probably to the partial decarboxylation of the proton-
ated carboxylic groups and oxidation reactions of the polyelec-
trolytes (Mimmo et al., 2005; Soares et al., 2004). Chitosan–
sodium alginate physical mixture shows an endothermic peak
at 110 C that can be probably explained due to the coales-cence of both isolated endothermic polymer peaks, whereas
exothermic peaks at 245 C and 300 C resulted from individ-
ual contribution of alginate and chitosan, respectively. In IR
spectra of IPEC, it could be seen that the peaks of the IPEC
were shifted from those of physical mixture. Exothermic peak
of IPEC appeared at 290 C, an intermediate and broader peak
value compared with isolated chitosan and sodium alginate,
which represents an interaction between both polymers. Endo-
thermic peak is also shifted to a higher temperature at 130 C
with a relative broader and shorter peak. This represents that
the formed IPEC is a different chemical entity than the mixture
of two polymers.
The X-ray diffraction of chitosan, sodium alginate and
IPEC is shown in Fig. 3. The powder X-ray diffraction pattern
of chitosan powder showed two prominent diffraction peaks at
10.6 (2h) and 19.64 (2h). A shoulder peak appears at 21.74
and also a minor peak appears at 26.62. The two prominent
crystalline peaks at 10.6 and 19.64 are typical ﬁngerprints
of chitosan which were related to the hydrated and anhydrous
crystals respectively (Mimmo et al., 2005) (Wan et al., 2003).
Sodium alginate shows peaks at 13.36 and 21.38, whereas
IPEC showed a peak at 21.66. The typical peaks of chitosan
disappeared and the IPEC showed an amorphous morphology
after complexing. The integration of sodium alginate into
chitosan disrupted the crystalline structure of chitosan, which
is due to the elimination of hydrogen bonding between amino
groups and hydroxyl groups in chitosan (Kim et al., 1993).
3.2. Pharmaceutical properties
The results of pharmaceutical properties are summarized in
Table 2. The matrix tablets showed a diameter of 8 mm with
negligible variation and therefore not included in the table.
All the formulations showed satisfactory values within the lim-
its of conventional oral tablets stated in the Indian Pharmaco-
poeia (Indian pharmacopeia, 2007).
3.3. Swelling studies
In vaginal pH 4.2, F2 formulation showed maximum swelling
at 8 h. F1 formulation exhibited less swelling than F2. F2 for-
mulation was found to have high 662% of swelling at 8 h. Fur-
ther, the addition of chitosan and sodium alginate in F3 and
F4 formulations reduces the swelling than F1 and F2 formula-
tions. Nearly the same degree of swelling was observed for F5
Table 3 Drug release kinetic parameters for the formulations.
Formulation Zero order Matrix Korsmeyer-Peppas
R K R K n K
F1
Vaginal pH 0.9700 14.328 0.9788 34.1764 0.7705 21.8835
Buccal pH 0.9906 1.5205 0.9563 3.5852 0.9291 1.7538
Rectal pH 0.9770 14.3480 0.7753 34.1419 0.7726 21.6978
F2
Vaginal pH 0.9980 11.9137 0.9235 27.7433 0.9464 12.8462
Buccal pH 0.9964 1.2622 0.9103 2.9246 1.0865 1.0718
Rectal pH 0.9967 12.7421 0.9445 29.9076 0.8613 16.1300
F3
Vaginal pH 0.9799 12.2565 0.9740 29.1354 0.7648 18.7170
Buccal pH 0.9063 1.6313 0.9920 3.9438 0.4840 4.0109
Rectal pH 0.9882 11.4832 0.8846 26.3793 1.1759 8.1070
F4
Vaginal pH 0.9871 11.8275 0.8809 27.1174 1.3717 6.0614
Buccal pH 0.9982 1.3597 0.9235 3.1648 1.0372 1.2634
Rectal pH 0.9874 11.3880 0.8830 26.1553 1.1348 8.5792
Figure 7 Ex vivo permeation studies of F5 & F6 formulation. ¤
F5, n F6. (mean ± SD, n= 3).
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deoxycholate does not signiﬁcantly alter the swelling in F5 and
F6. The comparison of degree of swelling of all formulations in
vaginal pH 4.2 is shown in Fig. 4a. F3 formulation exhibited
highest swelling in pH 6.8, IPEC along with chitosan and so-
dium alginate increases the swelling to 698% whereas F1 and
F2 formulations showed 623 and 654% swelling degrees
respectively. F4 formulation containing IPEC, chitosan and
sodium alginate in higher concentration than F3 formulation
showed decreased swelling than F3 formulation. Formulation
F4 was found to have 417% of swelling that is little lesser than
swelling in vaginal pH 4.2. This may be explained by the ability
of forming a gel layer in acidic pH which is lacking in buccal
pH 6.8. Similar swelling proﬁle was seen for F5 and F6 formu-
lations as of F4 formulation. Swelling proﬁles of formulations
in pH 6.8 are shown in Fig. 4b. Even in pH 7.4, the formula-
tion F2 is found to be having highest swelling. The swelling of
F3 formulation was found to be 663%. F4 formulation exhib-
ited swelling of 492% that is as nearly similar in pH 4.2 and
pH 6.8. Nearly same degree of swelling was observed for F5
and F6 as that of the formulation F4. Swelling proﬁles of for-
mulations in pH 7.4 are shown in Fig. 4c.These ﬁndings indicate that the presence of IPEC alone in
the matrix tablet exhibits a slow uniform pH independent
swelling degree and also the presence of chitosan and sodium
alginate in IPEC matrix tablets alters the swelling degree.
Therefore the mechanism of drug release from IPEC matrix
tablets was affected by the presence of chitosan and sodium
alginate.
3.4. Bioadhesion studies
The mucoadhesive strength for all the formulations is shown in
Fig. 5. F1 formulation containing only IPEC shows the least
detachment force this may be explained due to the lacking of
free functional groups which were probably involved in the
adhesion of the mucosa. F2 formulation having a higher con-
centration of IPEC still exhibited the least detachment force,
further addition of chitosan and sodium alginate to IPEC con-
centration in F3 formulation enhances the detachment force.
F4 formulation shows the highest detachment force, this may
be due to the availability of free functional groups. F5 & F6
formulations containing sodium deoxycholate does not have
any impact on the detachment force.
These ﬁndings indicate that the presence of IPEC alone
does not exhibit sufﬁcient bioadhesion hence the presence of
other polymers is necessary for the development of bioadhesive
matrix tablets. Therefore a suitable combination of polymers
along with IPEC is selected for producing sufﬁcient bioadhe-
sion without altering properties of IPEC.
3.5. In vitro drug release studies
In vitro drug release study as dissolution proﬁles of formula-
tion F1–F4 in pH 4.2, pH 6.8 and pH 7.4 is shown in
Fig. 6a, Fig. 6b and Fig. 6c respectively. 5-FU matrix tablets
were initially prepared from IPEC alone and the in vitro drug
release was investigated in buccal, vaginal and rectal pH. For-
mulations containing only IPEC (F1& F2) in all pH exhibited
controlled release properties. But F3 formulation retarded
Figure 8 X-ray radiographic images of buccal, vaginal and rectal cavity at 1 and 8 h after ingestion of BaSO4-loaded optimized F4
matrix tablet in rabbits.
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plained due to the addition of chitosan which forms gel at
acidic pH. Further, the increase in concentration of chitosan
in F4 formulation retards the drug release but later releases
the drug up to 95% that is desirable, this may be due to the
presence of sodium alginate that inhibits the gel forming ability
of chitosan in higher concentration. In case of buccal pH 6.8,
F3 formulation exhibits the initial burst effect about 45% of
the drug is released at the 1st hour that is due to the presence
of chitosan and sodium alginate inhibiting the controlled re-
lease effect of IPEC. Whereas in case of F4 formulation, the
initial burst effect is abolished with increase in the concentra-
tion of sodium alginate that forms a stiff gel along with IPECand hence retards the drug release. In pH 7.4, all the formula-
tions exhibit the controlled drug release without the initial
burst effect. Among all formulations, F4 formulation exhibits
an excellent and desirable drug release proﬁle. The presence of
chitosan and sodium alginate does not alter properties hence
desirable drug release proﬁle was seen for F4 formulation in
pH 7.4. Similar drug proﬁle was seen as in buccal and vaginal
pH. F5 & F6 formulations containing SDC exhibited similar
drug release proﬁle as F4 formulation (Data not mentioned).
To conﬁrm the similarity of F4 formulation dissolution
proﬁles in buccal, vaginal and rectal pH, the similarity factor
(F2) was used and was found above 80. Since the F2 values
were higher than 50, these results conﬁrmed that the drug re-
Hybrid drug delivery system for oropharyngeal, cervical and colorectal cancer – in vitro and in vivo evaluation 185lease proﬁles were almost similar for F4 formulation for buc-
cal, vaginal pH and rectal pH.
Kinetic parameters determined are shown in Table 3.
To ascertain drug release mechanism and release rate, the
release data were ﬁtted into release models using PCP Disso
V2.01 dissolution software. The models selected were of zero
order, Higuchi matrix and Korsmeyer-Peppas.
3.6. Ex vivo permeation studies
5-FU permeation from formulations F5 and F6 across sheep
mucosa over a period of 8 h is shown in Fig. 7. The maximum
permeation of 5-FU from F5 was 60% at 8 h compared with
98% from F6. Regression of the linear portions of the two
plots gave slopes and intercepts from which the permeation
ﬂux (slope divided by mucosal surface area) of F5 and F6
was calculated to be 5.01 and 8.6 mg/cm2/h, respectively.
In formulation F5 addition of SDC 2% increased the
cumulative percentage of drug permeated to 60%. This may
be due to SDC extracted only the mucosal lipid from the inter-
cellular spaces. Thus, this enhances the diffusivity of the 5-FU
via the paracellular or polar route. Further increase in concen-
tration of SDC (F6), i.e., 3%, increased the drug permeation
up to 98% thus SDC in 3% extracts lipids from the cell mem-
branes, along with the extraction of mucosal lipid from the
intercellular spaces by the formation of micelles. This resulted
in enhancing passive diffusivity of the 5-FU via transcellular
(crossing the cell membranes and entering the cell) and para-
cellular routes (Hoogstraate et al., 1997). It was mentioned
that SDC can also cause the uncoiling and extension of the
protein helices, which leads to opening of the polar pathways
for diffusion (Gandhi and Robinson, 1992). All these effects
might contribute to enhancing the permeation of the drug.
3.7. In vivo X-ray studies
After administration of the optimized formulation (F4), devel-
oped by using barium sulfate, the duration of the tablet in the
buccal, vaginal and rectal cavity was monitored by radiograms
(Fig. 8). The tablet adheres to the buccal, vaginal and rectal
mucosa. The buccal tablet swells and is retained till 8 h with
little reduction in tablet size, as the tablet swells certain part
of the tablet was swallowed by the rabbit thereby the tablet size
reduces. Whereas the tablet in the vaginal cavity swells in 1 h
and little reduction of size at 8 h. In the rectal cavity tablet re-
mained in the cavity till 8 h.
4. Conclusion
The IPEC between Chitosan and sodium alginate demon-
strated not only as a potential excipient for control release in
the matrix system but also possesses pH independent drug re-
lease for the delivery of 5-FU. The matrix system with a suit-
able combination of chitosan and sodium alginate was able to
produce desired drug release, bioadhesion and swelling. The
desired bioadhesion can be achieved only with the addition
of chitosan and sodium alginate; hence asuitable combination
played a key role in the bioadhesion and subsequently main-
tains the pH independent drug release without initial burst re-
lease pattern. The addition of Sodium deoxycholate to thematrix tablets is also necessary to attain optimum drug
permeation.Acknowledgment
The authors wish to thank the JSS University, Mysore, India
for providing the facilities to complete this work.
References
Augst, A.D., Kong, H.J., Mooney, D.J., 2006. Alginate hydrogels as
biomaterials. Macromol. Biosci. 6, 623–633.
Baruch, L., Machluf, M., 2006. Alginate-chitosan complex coacerva-
tion for cell encapsulation: effect on mechanical properties and on
long-term viability. Biopolymers 82, 570–579.
Berger, J., Reist, M., Mayer, J.M., Felt, O., Peppas, N.A., Gurny, R.,
2004. Structure and interactions in covalently and ionically
crosslinked chitosan hydrogels for biomedical applications. Eur.
J. Pharm. Biophar. 57, 19–34.
Bruno, S., Domingos, F., Francisco, V., Antonio, R., 2006. Charac-
terization of insulin-loaded alginate nanoparticles produced by
ionotropic pre-gelation through DSC and FTIR studies. Carbohy-
dr. Polym. 66, 1–7.
Calavresi, P., Chabner, BA., 1996. In: Hardman, J.G., Limbird, L.E.,
Perry, B.M., Raymond, W.R. (Eds.), Goodman & Gilmans. The
pharmacological basis of therapeutics. McGraw-Hill, New Delhi,
pp. 125–1232.
Chen, T.W., Chang, S.J., Cheng-Chie Niu, G., Hsu, Y.T., Kuo, S.M.,
2006. Alginate-coated chitosan membrane for guided tissue regen-
eration. J. Appl. Polym. Sci. 102, 4528–4534.
Dang, J.M., Leong, K.W., 2006. Natural polymers for gene delivery
and tissue engineering. Adv. Drug. Deliv. Rev. 58, 487–499.
Deshmukh, V.N., Jadhav, J.K., Sakarkar, D.M., 2009. Formulation
and in vitro evaluation of theophylline anhydrous bioadhesive
tablets. Asian. J. Pharm. 3, 54–58.
Dhiman, M., Yedurkar, P.D., Sawant, K.K., 2008. Formulation,
characterization and in vitro evaluation of bioadhesive gels
containing 5-Flurouracil. Pharm. Dev. Tech. 13 (1), 15–25.
Diasio, R.B., Harris, B.E., 1989. Clinical pharmacology of 5-ﬂuoro-
uracil. Clin. Pharmacokinet. 16, 215–237.
colling, Dollery (Ed.), 1999. Therapeutic drugs, 2nd ed. Churchill
livingstone, Edinburgh, pp. F103–F108, vol. 1.
Gandhi, R., Robinson, J., 1992. Mechanisms of penetration enhance-
ment for transbuccal delivery of salicylic acid. Int. J. Pharm. 85,
129–140.
George, M., Abraham, T.E., 2006. Polyionic hydrocolloids for the
intestinal delivery of protein drugs: alginate and chitosan-A review.
J. Control. Rel. 114, 1–14.
Gombotz, W.R., Wee, S.F., 1998. Protein release from alginate
matrices. Adv. Drug. Deliv. Rev. 31, 267–285.
Hoogstraate, A.J., Wertz, P.W., Squier, C.A., Bos Van Geest, A.,
Abraham, W., Garrison, M.D., Verhoef, J.C., Junginger, H.E.,
Bodde, H.E., 1997. Effects of the penetration enhancer glyco-
deoxycholate on the lipid integrity in porcine buccal epithelium
in vitro. Eur. J. Pharm. Sci. 5, 189–198.
Indian pharmacopeia. The Indian pharmacopeia commission. Ghaz-
iabad (India):2007.
Iwasaki, N., Yamane, S.T., Majima, T., Kasahara, Y., Minami, A.,
Harada, K., Nonaka, S., Maekawa, N., Tamura, H., Tokura, S.,
Shiono, M., Monde, K., Nishimura, S., 2004. Feasibility of
polysaccharide hybrid materials for scaffolds in cartilage tissue
engineering: evaluation of chondrocyte adhesion to polyion com-
plex ﬁbers prepared from alginate and chitosan. Biomacromole-
cules 5, 828–833.
186 M.S. Pendekal, P.K. TegginamatKim, J.H., Lee, Y.M., Kim, J.H., Lee, Y.M., 1993. Synthesis and
properties of diethylaminoethyl chitosan. Polymer. 34, 1952–1957.
Lawrie, G., Keen, I., Drew, B., 2007. Interactions between alginate and
chitosan biopolymers characterized using FTIR and XPS. Bio-
macromolecules 8, 2533–2541.
Li, Z., Ramay, H.R., Hauch, K.D., Xiao, D., Zhang, M., 2005.
Chitosan-alginate hybrid scaffolds for bone tissue engineering.
Biomaterials 26, 3919–3928.
Libero, I.G., Viviana, D.C., Giulia, G., Maria, G.S., Carlo, P.,
Guiseppina, C., Ada, M.F., 2010. 5-Flurouracil buccal tablets for
Locoregional chemotherapy of oral squamous cell carcinoma:
formulation, drug release and histological effects on reconstituted
human oral epithelium and porcine buccal mucosa. Current. Drug
Delivery 7 (2), 109–117.
Madihally, S.V., Matthew, H.W.T., 1999. Porous chitosan scaffolds
for tissue engineering. Biomaterials 20, 1133–1142.
Mathew, S., Brahmakumar, M., Abraham, T.E., 2006. Microstruc-
tural imaging and characterization of the mechanical, chemical,
thermal, and swelling properties of starch-chitosan blend ﬁlms.
Biopolymers 82, 176.
Mimmo, T., Marzadori, C., Montecchio, D., Gessa, C., 2005.
Characterisation of Ca- and Al-pectate gels by thermal analysis
and FT-IR spectroscopy. Carbohydr. Res. 340 (16), 2510–2519.
Mohamed, S.P., Pramod, K.T., 2012a. Formulation and evaluation of
a bioadhesive patch for buccal delivery of tizanidine. Acta. Pharm.
Sin. B. 2 (3), 318–324.
Mohamed, S.P., Pramod, K.T., 2012b. A novel bucco-vaginal
controlled release drug delivery system of miconazole nitrate for
candidiasis-design and evaluation. Lat. Am. J. Pharm. 31 (3), 461–
468.
Moustanﬁne, R.I., Kabonova, T.V., Kemonova, V.A., Van den
Mooter, G., 2005. Characteristics of interpolyelectrolyte complexes
of Eudragit E100 with Eudragit L100. J. control. rel. 103, 191–198.
Nam, K., Watanabe, J., Ishihara, K., 2004. The characteristics of
spontaneously forming physically cross-linked hydrogels composed
of two water soluble phospholipids polymers for oral drug delivery
carrier I: Hydrogel dissolution and insulin release under neutral pH
condition. Eur. J. Pharm. Sci. 23, 251–270.
Neto, C.G.T., Giacometti, J.A., Job, A.E., Ferreira, F.C., Fonseca,
J.L.C., Pereira, M.R., 2005. Thermal analysis of chitosan based
networks. Carbohydr. Polym. 62, 97–103.Peppas, N.A., Khare, A.R., 1993. Preparation, structure and diffusion
behavior of hydrogels in controlled release. Adv. Drug. Deliv. Rev.
11, 1–35.
Rudy, B.C., Senkowski, B.Z., 1973. Flurouracil. In: Florey, k. (Ed.),
Analytical proﬁles of drug substances. Academic press, New York,
pp. 221–244, 2.
Sankalia, M.G., Mashru, R.C., Sankalia, J.M., Sutariya, V.B., 2007.
Reversed chitosan–alginate polyelectrolyte complex for stability
improvement of alpha-amylase: optimization and physicochemical
characterization. Eur. J. Pharm. Biopharm. 65, 215.
Sarmento, B., Ribeiro, A., Veiga, F., Ferreira, D., 2006. Development
and characterization of new insulin containing polysaccharide
nanoparticles. Colloids Surf. B, Biointerfaces. 53, 193.
Singh, B.N., Singh, R.B., Singh, J., 2005. Effects of ionization and
penetration enhancers on the Transdermal delivery of 5-ﬂurouracil
through excised human stratum corneum. Int. J. pharm. 298, 98–
107.
Soares, J.P., Santos, J.E., Chierice, G.O., Cavalheiro, E.T.G., 2004.
Thermal behavior of alginic acid and its sodium salt. Ecletica.
Quimica. 29 (2), 57–63.
Stuart, B., 2004. Infrared Spectroscopy: Fundamentals and Applica-
tions. John Wiley & Sons Ltd., West Sussex, England.
Takahashi, T., Takayama, K., Machida, Y., Nagai, T., 1990. Char-
acteristics of polyion complexes of chitosan with sodium alginate
and sodium polyacrylate. Int. J. Pharm. 61, 35–41.
Tien, L.C., Lacroix, M., Szabo, P.I., Mateescu, M.A., 2003. N-
acylated chitosan: hydrophobic matrices for controlled drug
release. J. Control. Rel. 93, 1–13.
Wan, Y., Creber, K.A.M., Peppley, B., Bui, V.T., 2003. Synthesis,
characterization and ionic conductive properties of phosphorylated
chitosan membranes. Macromol. Chem. Physiol. 204, 850–858.
Williams, A.C., Barry, B.W., 1991. Terpenes and the lipid-protein
partitioning theory of the skin penetration enhancement. Pharm.
res. 8, 17–24.
Woolfson, A.D., McCafferty, D.F., McCarron, P.A., Price, J.H., 1995.
A bioadhesive patch cervical drug delivery system for the admin-
istration of 5-ﬂurouracil to cervical tissue. J. control. rel. 35, 49–58.
Xiaoxia, Li., Hongguo, Xie., Junzhang, Lin., Weiyang, Xie., Xiaojun,
Ma., 2009. Characterization and biodegradation of chitosan–
alginate polyelectrolyte complexes. Polymer. Degrad. Stab. 94, 1–6.
